Sanofi UroXatral Approval For BPH Includes Phase IV QT Study Commitment
Executive Summary
Sanofi-Synthelabo's UroXatral Phase IV study will examine potential QT prolongation of alfuzosin in combination with a phosphodiesterase inhibitor erectile dysfunction agent following June 12 approval of the drug